Among these compounds, KCC009 blocks TG2-mediated fibronectin remodeling in both in vitro and in vivo studies [205,206] and increases sensitivity in mice harboring glioblastomas to carmustine chemotherapy, leading to improved survival [205]. This evidence concerns the gene TGM2 and glioblastoma.